Title
Author
DOI
Article Type
Special Issue
Volume
Issue
1Department of Gynaecology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, 330036 Nanchang, Jiangxi, China
2Department of Plastic and Aesthetic, Jiangxi Provincial Children’s Hospital, The Affiliated Children’s Hospital of Nanchang Medical College, 330036 Nanchang, Jiangxi, China
*Corresponding Author(s):yu_dr15@163.com (Gang Yu)
| History | Published: 15 October 2026 |
| Copyright: | ©2026 The Author(s). Published by MRE Press. |

No abstract available.
Cite this article
Xin Hu, Pingliang Jin, Wenqun Luo, Gang Yu. Correction: CPNE1 as prognostic marker and regulator of cell growth and glycolysis in endometrial cancer. European Journal of Gynaecological Oncology. 2026; 47(3): 156-156. doi: 10.22514/ejgo.2026.053
In the original publication [1], references [4], [6], [17], and [19] have been replaced (or corrected) to improve precision and relevance. The correct references are as follows:
[4] Dexter J, Lips E, DiSilvestro P. Adjuvant therapy in node-positive endometrial cancer: a focus on chemotherapy. Current Oncology Reports. 2022; 24: 1677–1683.
[6] Cao J, Cao R, Liu Y, Dai T. CPNE1 mediates glycolysis and metastasis of breast cancer through activation of PI3K/AKT/HIF-1α signaling. Pathology, Research and Practice. 2023; 248: 154634.
[17] Hassan D, Menges CW, Testa JR, Bellacosa A. AKT kinases as therapeutic targets. Journal of Experimental & Clinical Cancer Research. 2024; 43: 313.
[19] Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. International Journal of Biological Sciences. 2024; 20: 3113–3125.
The authors state that these adjustments do not alter the study design, data, results, interpretation, or the overall scientific conclusions of the work.